Source: AMA Morning Rounds 8/10/2010
Tuesday, August 10, 2010
Source: AMA Morning Rounds 8/10/2010
Monday, July 26, 2010
Several strategies may be worth trying to prevent Alzheimer's
Source: AMA Morning Rounds 7/26/2010
Several strategies may be worth trying to prevent Alzheimer's.
Friday, July 23, 2010
Source: AMA Morning Rounds 7/23/2010
Scientists identify possible connection between IBS, brain.
Monday, July 12, 2010
Brain decline reduced with activity, vitamin D and tea
Source: AMA Morning Rounds 7/12/2010
Physical activity, tea-drinking, sufficient vitamin D levels may help reduce risk of brain decline, studies suggest.
Monday, April 26, 2010
Computer brain games may not improve cognitive ability.
Source: AMA Morning Rounds 4/21/2010
Computer brain games may not improve cognitive ability.
Wednesday, January 6, 2010
FDA investigates 300 radiation overdoses from CT scans.
Source: AMA Morning Rounds 12/16/09
FDA investigates 300 radiation overdoses from CT scans.
Tuesday, January 5, 2010
Bedside exam may be superior to CT in detecting post-brain surgery complications.
Source: AMA Morning Rounds 12/29/09
Bedside exam may be superior to CT in detecting post-brain surgery complications.
Monday, January 4, 2010
Gingko biloba not effective in preventing cognitive decline, improving memory.
Source: AMA Morning Rounds 12/30/09; JAMA. 2009; 302:2663-2670
Gingko biloba not effective in preventing cognitive decline, improving memory.
Ginkgo biloba for Preventing Cognitive Decline in Older Adults
A Randomized Trial
JAMA. 2009;302(24):2663-2670.
Context The herbal product Ginkgo biloba is taken frequently with the intention of improving cognitive health in aging. However, evidence from adequately powered clinical trials is lacking regarding its effect on long-term cognitive functioning.
Objective To determine whether G biloba slows the rates of global or domain-specific cognitive decline in older adults.
Design, Setting, and Participants The Ginkgo Evaluation of Memory (GEM) study, a randomized, double-blind, placebo-controlled clinical trial of 3069 community-dwelling participants aged 72 to 96 years, conducted in 6 academic medical centers in the United States between 2000 and 2008, with a median follow-up of 6.1 years.
Intervention Twice-daily dose of 120-mg extract of G biloba (n = 1545) or identical-appearing placebo (n = 1524).
Main Outcome Measures Rates of change over time in the Modified Mini-Mental State Examination (3MSE), in the cognitive subscale of the Alzheimer Disease Assessment Scale (ADAS-Cog), and in neuropsychological domains of memory, attention, visual-spatial construction, language, and executive functions, based on sums of z scores of individual tests.
Results Annual rates of decline in z scores did not differ between G biloba and placebo groups in any domains, including memory (0.043; 95% confidence interval [CI], 0.034-0.051 vs 0.041; 95% CI, 0.032-0.050), attention (0.043; 95% CI, 0.037-0.050 vs 0.048; 95% CI, 0.041-0.054), visuospatial abilities (0.107; 95% CI, 0.097-0.117 vs 0.118; 95% CI, 0.108-0.128), language (0.045; 95% CI, 0.037-0.054 vs 0.041; 95% CI, 0.033-0.048), and executive functions (0.092; 95% CI, 0.086-0.099 vs 0.089; 95% CI, 0.082-0.096). For the 3MSE and ADAS-Cog, rates of change varied by baseline cognitive status (mild cognitive impairment), but there were no differences in rates of change between treatment groups (for 3MSE, P = .71; for ADAS-Cog, P = .97). There was no significant effect modification of treatment on rate of decline by age, sex, race, education, APOE*E4 allele, or baseline mild cognitive impairment (P > .05).
Conclusion Compared with placebo, the use of G biloba, 120 mg twice daily, did not result in less cognitive decline in older adults with normal cognition or with mild cognitive impairment.
Trial Registration clinicaltrials.gov Identifier: NCT00010803
Author Affiliations: Departments of Neurology (Drs Snitz, Saxton, Lopez, and DeKosky and Ms Dunn) and Epidemiology (Ms Ives), University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Biostatistics, University of Washington, Seattle (Drs O’Meara and Arnold); Department of Mental Health, Johns Hopkins Medical Institutions, Baltimore, Maryland (Dr Carlson); Departments of Psychiatry and Behavioral Medicine (Dr Rapp) and Internal Medicine (Geriatrics/Gerontology), School of Medicine (Dr Sink), Wake Forest University, Winston-Salem, North Carolina; and School of Medicine, University of Virginia, Charlottesville (Dr DeKosky).
Wednesday, March 18, 2009
Metabolic disorders linked to cognitive decline
Metabolic disorders linked to cognitive decline
March 17, 2009 Allison Gandey
Edited from Medscape Medical News—a professional news service of WebMD
New York, NY and Seattle, WA - Evidence is mounting that metabolic and neurological diseases share common risk factors, according to two studies in the March 2009 issue of the Archives of Neurology.
"Preventing heart disease, stroke, and diabetes—or making sure these conditions are well managed in patients diagnosed with them—can potentially slow the disease progression of Alzheimer's," senior author on one of the studies, Dr Yaakov Stern (Columbia University, New York), said in a news release. Stern et al, led by Dr Elizabeth Helzner (Columbia University) hypothesized that vascular factors such as heart disease, stroke, diabetes, hypertension, smoking, and blood lipid levels may predict the progression of Alzheimer's disease [1]. The group studied 156 patients followed for a mean of 3.5 years. Participants were from the Washington Heights and Inwood Columbia Aging Project, a multiethnic, community-based, prospective study of aging in northern Manhattan.
Researchers found that patients with a history of diabetes and elevated levels of cholesterol, especially LDL cholesterol, had faster cognitive decline. In fact, each 10-U increase in cholesterol and LDL cholesterol was associated with a 0.10-standard-deviation decrease in cognitive score per year of follow-up (p<0.001 for total cholesterol; p=0.001 for LDL cholesterol).
Investigators found that a history of heart disease and stroke were associated with cognitive decline only in carriers of the APOE e4 allele.
"These findings indicate that controlling vascular conditions may be one way to delay the course of Alzheimer's, which would be a major development in the treatment of this devastating disease," Stern said.Fluctuations in weight may boost dementia risk
In the second study published in the same issue of the Archives of Neurology, investigators show that obese middle-aged adults and underweight elderly people have an increased dementia risk [2].
Using data from the Cardiovascular Health Study, researchers studied the body-mass index (BMI) of participants at mid- and late life. Patients were from a community-dwelling sample at four US sites.
Investigators included 2798 people. Of these, 480 had incident dementia, 245 had Alzheimer's disease, and 213 had vascular dementia.
They found that middle-aged patients who were obese had an increased risk for dementia (BMI >30 vs normal-weight BMI 20 to 25), adjusted for demographics (hazard ratio 1.39; 95% CI 1.03-1.87), although this observation was weakened after adjustment for cardiovascular risk factors (hazard ratio 1.36; 95% CI 0.94-1.95).
These results help explain the 'obesity paradox.'
But the risk estimates were reversed in assessments of late-life BMI. Underweight people, those with a BMI of less than 20, had an increased risk for dementia (hazard ratio 1.62; 95% CI 1.02-2.64). Surprisingly, being overweight later in life was not associated with an increased risk (hazard ratio 0.92; 95% CI 0.72-1.18), and being obese reduced the risk for dementia (hazard ratio 0.63; 95% CI 0.44-0.91).
"These results help explain the 'obesity paradox,' " the researchers, led by Dr Annette Fitzpatrick (University of Washington, Seattle), write. "Differences in dementia risk across time are consistent with physical changes in the trajectory toward disability."
These findings suggest that the predictive ability of BMI changes across time, they note
"Weight loss occurs with comorbidities at older ages and is often reflective of poor health," write Fitzpatrick and her team. "Weight loss, along with psychological, behavioral, and mobility problems, is one of the principal manifestations of Alzheimer's disease. Weight loss may predate dementia onset by as much as 10 years."
The researchers conclude: "These results reinforce the necessity of monitoring weight loss closely in older adults."
The complete contents of Medscape Medical News, a professional news service of WebMD, can be found at www.medscape.com, a website for medical professionals.
Sources
Helzner EP, Luchsinger JA, Scarmeas N, et al. Contribution of vascular risk factors to the progression in Alzheimer disease. Arch Neurol 2009; 66:343-348.
Fitzpatrick AL, Kuller LH, Lopez OL, Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch Neurol 2009; 66:336-342.
Related links
Adherence to Mediterranean diet reduces risk of major chronic diseases [Prevention > Prevention; Sep 12, 2008]
Heart disease linked to poor cognitive function in middle age [Brain/Kidney/Peripheral > Brain/Kidney/Peripheral; Jul 23, 2008]
Low HDL-C associated with poor memory [HeartWire > Brain/Kidney/Peripheral; Jun 30, 2008]
High cholesterol linked to increased AD risk [HeartWire > Medscape Medical News; Nov 06, 2006]
Low cholesterol linked to reduced cognitive function [HeartWire > News; Mar 23, 2005]
Lipid metabolism abnormalities observed in brain aging and Alzheimer's disease [HeartWire > News; Feb 15, 2004]
Friday, February 27, 2009
Green and Black Tea Consumption and Risk of Stroke. A Meta-Analysis
Green and Black Tea Consumption and Risk of Stroke. A Meta-Analysis
Lenore Arab PhD*; From UCLA's School of Medicine, Los Angeles, Calif.
* To whom correspondence should be addressed. E-mail: Larab@ucla.edu.
Background and Purpose—Experimental models of stroke provide consistent evidence of smaller stroke volumes in animals ingesting tea components or tea extracts. To assess whether a similar association of black or green tea consumption with reduced risk is evident in human populations, we sought to identify and summarize all human clinical and observational data on tea and stroke.
Methods—We searched PubMed and Web of Science for all studies on stroke and tea consumption in humans with original data, including estimation or measurement of tea consumption and outcomes of fatal or nonfatal stroke. Data from 9 studies involving 4378 strokes among 194 965 individuals were pooled. The main outcome was the occurrence of fatal or nonfatal stroke. We tested for heterogeneity and calculated the summary effect estimate associated with consumption of 3 cups of tea (green or black) per day using random-effects and fixed-effects models for the homogeneous studies. Publication bias was also evaluated.
Results—Regardless of their country of origin, individuals consuming 3 cups of tea per day had a 21% lower risk of stroke than those consuming <1> 0.85). The proportion of heterogeneity not explained by chance alone was 23.8%.
Conclusions—Although a randomized clinical trial would be necessary to confirm the effect, this meta-analysis suggests that daily consumption of either green or black tea equaling 3 cups per day could prevent the onset of ischemic stroke.
Key words: black tea • Camelia sinensis • green tea • ischemic stroke • theophylline
Friday, December 19, 2008
Association of Alcohol Consumption With Brain Volume in the Framingham Study
Moral of the story: You have probably heard about the myth that drinking kills brain cells. Well, thanks to a very large heart study in Framinghman, MA that started back in 1948 we now know that drinking copious amounts of alcohol over an extended period of time will shrink the size of your brain. Thats right, the more you drink the smaller your brain will be (especially if you are female). The good news is that with limited amounts of alcohol your heart will be loving life, even if your brain isn't as lucky. However, there is also evidence that large quantities of alcohol are bad for your heart.
Association of Alcohol Consumption With Brain Volume in the Framingham Study
Carol Ann Paul, MS; Rhoda Au, PhD; Lisa Fredman, PhD; Joseph M. Massaro, PhD; Sudha Seshadri, MD; Charles DeCarli, MD; Philip A. Wolf, MD
Arch Neurol. 2008;65(10):1363-1367.
Background While adults who drink low to moderate amounts of alcohol have lower rates of cardiovascular disease than other adults, the effect of alcohol on the brain is less clear. There is evidence that drinking large amounts of alcohol is related to brain atrophy. It is uncertain what the effects of low to moderate consumption might be.
Objective To determine whether consumption of smaller amounts of alcohol negatively affects brain volume or is protective in reducing the well-documented age-related decline in brain volume.
Design Total cerebral brain volume (TCBV) was computed, correcting for head size. Multivariate linear regression models were used to evaluate the association between 5 categories of alcohol consumption (abstainers, former drinkers, low, moderate, high) and TCBV, adjusting for age, sex, education, height, body mass index (calculated as weight in kilograms divided by height in meters squared), and the Framingham Stroke Risk Profile. Pairwise comparisons were also conducted between the alcohol consumption groups.
Participants A total of 1839 subjects from the Framingham Offspring Study who had magnetic resonance imaging of the brain between 1999 and 2001.
Results Most participants reported low alcohol consumption, and men were more likely than women to be moderate or heavy drinkers. There was a significant negative linear relationship between alcohol consumption and TCBV (r = –0.25; P < .001). This relationship was modified by sex, with alcohol consumption having a stronger association with TCBV in women than in men (r = –0.29 vs –0.20). Conclusions In contrast to studies on cardiovascular disease, this study found that moderate alcohol consumption was not protective against normal age-related differences in total brain volume. Rather, the more alcohol consumed, the smaller the total brain volume.
Author Affiliations: Neuroscience Program, Wellesley College, Wellesley, Massachusetts (Ms Paul); Departments of Neurology (Drs Au, Seshadri, and Wolf), Epidemiology (Ms Paul and Dr Fredman), and Biostatistics, Boston University School of Public Health, Boston, Massachusetts (Dr Massaro); Department of Mathematics & Statistics, Boston University, Boston, Massachusetts (Dr Massaro); Framingham Heart Study, Framingham, Massachusetts (Drs Au, Massaro, Seshadri, and Wolf); and Department of Neurology and Center for Neuroscience, University of California, Davis, California (Dr DeCarli).